表阿霉素序贯多西紫杉醇化疗用于三阴乳腺癌的效果、肿瘤标志物及毒副反应比较
盛树海
郑进 （ 唐山工人医院 ）
佟易凡
Abstract
摘要：目的：探讨表阿霉素序贯多西紫杉醇化疗用于三阴乳腺癌的效果及对肿瘤标志物含量的影响，以及药物所致毒副反应情况。方法：2013年6月-2016年10月间在本院接受治疗的晚期三阴乳腺癌患者108例，回顾性分析其化疗方案并分为：接受表阿霉素联合多西紫杉醇化疗的联合组55例、接受表阿霉素序贯多西紫杉醇化疗的序贯组53例。两组治疗6疗程后对比近期疗效、肿瘤标志物[组织多肽特异性抗原（TPA）、糖类抗原15-3（CA15-3）、糖类抗原125（CA125）、癌胚抗原（CEA）]含量及毒副反应发生情况的差异，随访并观察远期生存情况。结果：治疗后，两组患者的疾病控制率、治疗有效率及血清肿瘤标志物含量的差异无统计学意义（P>0.05）；序贯组患者白细胞抑制、血小板抑制、口腔溃疡、恶心呕吐的发生率低于联合组（P<0.05）。随访2年发现，序贯组患者的无进展生存时间、平均生存时间长于联合组患者，整体生存情况优于联合组患者（P<0.05）。结论：表阿霉素序贯多西紫杉醇化疗治疗三阴乳腺癌的疗效与联合治疗相当，但其毒副作用相对较小，对延长远期生存时间、提升生存率具有积极作用。
Keywords
三阴乳腺癌; 表阿霉素; 多西紫杉醇; 肿瘤标志物; 毒副反应Full Text
PDFReferences
[1]Hou X, Niu Z, Liu L, et al. miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression[J]. OncolLett, 2019,17(1):990-998.
[2]Kalapanida D, Zagouri F, Gazouli M, et al. Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study[J]. Oncotarget, 2018,9(97):36906-36913.
[3]Brisard D, Eckerdt F, Marsh LA, et al. Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer[J]. Oncotarget, 2018,9(99):37305-37318.
[4]鲍云华,李俭杰.介绍新的实体瘤治疗反应评价标准(RECIST)[J].中国肺癌杂志, 2005,8（1）:77-78.
[5]表阿霉素及顺铂联合治疗子宫肉瘤的疗效及毒副反应分析[J].现代诊断与治疗, 2015,8（6）:1259-1260.
[6]朱兵.多西紫杉醇联合洛铂治疗晚期非小细胞肺癌临床疗效观察[J].北方药学, 2018,15（11）:163-164.
[7]Fiala O, Finek J, Buchler T, et al. The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study[J]. Target Oncol, 2015,10(4):549-555.
[8]Treska V,Topolcan O, Zoubkova V,et al. Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases[J]. Anticancer Res, 2018,38(6):3647-3652.
[9]Choi JW, Moon BI, Lee JW, et al. Use of CA15 3 for screening breast cancer: An antibody lectin sandwich assay for detecting glycosylation of CA15 3 in sera[J]. Oncol Rep, 2018,40(1):145-154.
[10]Tang S, Wei L, Sun Y, et al. CA153 in Breast Secretions as a Potential Molecular Marker for Diagnosing Breast Cancer: A Meta Analysis[J]. PLoS One, 2016,11(9):e0163030.
[11]Nazmeen A, Maiti S, Mandal K, et al. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease[J]. Med Chem, 2017,13(8):796-804.
[12]Babic A, Cramer DW, Kelemen LE, et al. Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium[J]. Cancer Causes Control, 2017,28(5):59-468.
[13]Yang H, Zhou L, Wang S, et al. Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?[J]. Medicine (Baltimore), 2018,97(40):e12690.
[14]Coté D, Eustace A, Toomey S, et al. Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel,carboplatin and trastuzumab (TCH)[J]. PLoS One, 2018,13(8):e0200996.
[15]Penault-Llorca F, Filleron T, Asselain B, et al. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive,hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)[J]. BMC Cancer, 2018,18(1):526.
[2]Kalapanida D, Zagouri F, Gazouli M, et al. Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study[J]. Oncotarget, 2018,9(97):36906-36913.
[3]Brisard D, Eckerdt F, Marsh LA, et al. Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer[J]. Oncotarget, 2018,9(99):37305-37318.
[4]鲍云华,李俭杰.介绍新的实体瘤治疗反应评价标准(RECIST)[J].中国肺癌杂志, 2005,8（1）:77-78.
[5]表阿霉素及顺铂联合治疗子宫肉瘤的疗效及毒副反应分析[J].现代诊断与治疗, 2015,8（6）:1259-1260.
[6]朱兵.多西紫杉醇联合洛铂治疗晚期非小细胞肺癌临床疗效观察[J].北方药学, 2018,15（11）:163-164.
[7]Fiala O, Finek J, Buchler T, et al. The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study[J]. Target Oncol, 2015,10(4):549-555.
[8]Treska V,Topolcan O, Zoubkova V,et al. Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases[J]. Anticancer Res, 2018,38(6):3647-3652.
[9]Choi JW, Moon BI, Lee JW, et al. Use of CA15 3 for screening breast cancer: An antibody lectin sandwich assay for detecting glycosylation of CA15 3 in sera[J]. Oncol Rep, 2018,40(1):145-154.
[10]Tang S, Wei L, Sun Y, et al. CA153 in Breast Secretions as a Potential Molecular Marker for Diagnosing Breast Cancer: A Meta Analysis[J]. PLoS One, 2016,11(9):e0163030.
[11]Nazmeen A, Maiti S, Mandal K, et al. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease[J]. Med Chem, 2017,13(8):796-804.
[12]Babic A, Cramer DW, Kelemen LE, et al. Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium[J]. Cancer Causes Control, 2017,28(5):59-468.
[13]Yang H, Zhou L, Wang S, et al. Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?[J]. Medicine (Baltimore), 2018,97(40):e12690.
[14]Coté D, Eustace A, Toomey S, et al. Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel,carboplatin and trastuzumab (TCH)[J]. PLoS One, 2018,13(8):e0200996.
[15]Penault-Llorca F, Filleron T, Asselain B, et al. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive,hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)[J]. BMC Cancer, 2018,18(1):526.
Copyright © 2019 盛树海，郑进，佟易凡
Publishing time:2019-09-30
This work is licensed under a Creative Commons Attribution 4.0 International License
Email
Location